A detailed history of Orbimed Advisors LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 10,124,576 shares of PASG stock, worth $6.38 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
10,124,576
Previous 10,124,576 -0.0%
Holding current value
$6.38 Million
Previous $13.7 Million 41.48%
% of portfolio
0.19%
Previous 0.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.82 - $1.19 $977,913 - $1.42 Million
1,192,577 Added 13.35%
10,124,576 $9.52 Million
Q2 2022

Aug 15, 2022

BUY
$1.63 - $3.46 $2.61 Million - $5.54 Million
1,600,000 Added 21.82%
8,931,999 $21.1 Million
Q1 2022

May 16, 2022

BUY
$2.66 - $6.49 $981,806 - $2.4 Million
369,100 Added 5.3%
7,331,999 $22.7 Million
Q1 2020

May 15, 2020

BUY
$8.86 - $22.2 $61.7 Million - $155 Million
6,962,899 New
6,962,899 $110 Million

Others Institutions Holding PASG

About Passage BIO, Inc.


  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $34.3M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.